Cairo Pharmaceuticals results, Q1 2022
Net profit, assets, equity and cash flow for Q1 2022, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit31.3 millionEGP
Total assets1.12 billionEGP
Shareholders' equity665 millionEGP
Operating cash flow30.35 millionEGP
In short
- Cairo Pharmaceuticals's net profit for Q1 2022 was about 31.3 million EGP.
- Total assets at the end of Q1 2022 were about 1.12 billion EGP, and shareholders' equity about 665 million EGP.
- Operating cash flow for Q1 2022 was positive at 30.35 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit31.3 million——
Gross profit71.46 million——
Total assets1.12 billion——
Total liabilities457 million——
Shareholders' equity665 million——
Total liabilities and equity1.12 billion——
Operating cash flow30.35 million——
Investing cash flow14.86 million——
Financing cash flow———
Net change in cash45.21 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Cairo Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy